20 years of Cure Parkinson's
We’re here for the cure! This year marks 20 years since Cure Parkinson’s was founded by four people living with Parkinson’s who felt that nobody was taking a cure seriously enough and that there was an urgent need for a focused approach to curative research...
Learn more
Webinar – Prodromal Parkinson’s
Presented by the Journal of Parkinson’s Disease, Cure Parkinson’s and Van Andel Institute. Prodromal Parkinson’s is the stage at which individuals exhibit signs and symptoms that indicate a higher than average risk of developing motor symptoms and a diagnosis of Parkinson’s in the future. The…
A biomarker for Parkinson’s?
A research report published this week, highlights a protein that could represent the first ‘biomarker’ for Parkinson’s progression.
The epigenetics of Parkinson’s.
Researchers at the Van Andel Institute in Grand Rapids (Michigan) have identified a “master regulator” gene switch that may protect the brain from neurodegenerative processes associated with Parkinson’s.
DENALI and Biogen team up against LRRK2
The biotech company Denali have announced that they have signed a collaborative deal with the pharmaceutical company Biogen.
MODAG: positive phase 1 results of potential new Parkinson’s drug
Supported by Cure Parkinson’s, German Biotech company MODAG have announced positive results from their phase 1 clinical trial of Anle138b for Parkinson’s.